期刊
NATURE REVIEWS CANCER
卷 16, 期 2, 页码 99-109出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc.2015.17
关键词
-
类别
资金
- Cancer Council of Victoria [1044722]
- Lady Tata Memorial Trust
- Leukaemia Foundation Australia
- Cure Brain Cancer Innovation Grant
- Australian National Health and Medical Research Council (NHMRC) [1016701]
- Australian National Health and Medical Research Council (NHMRC) (NHMRC SPRF) [1020363, 1020136]
- Leukemia and Lymphoma Society (SCOR) [7001-13]
- Estate of Anthony (Toni) Redstone OAM
- Melbourne International Research Scholarship (University of Melbourne)
- Melbourne International Fee Remission Scholarship (University of Melbourne)
- Australian Postgraduate Award
- Cancer Therapeutics CRC top-up scholarship
- Australian Government Independent Research Institutes Infrastructure Support (IRISS)
- Victorian State Government OIS
The 'hallmarks of cancer' are generally accepted as a set of genetic and epigenetic alterations that a normal cell must accrue to transform into a fully malignant cancer. It follows that therapies designed to counter these alterations might be effective as anti-cancer strategies. Over the past 30 years, research on the BCL-2-regulated apoptotic pathway has led to the development of small-molecule compounds, known as 'BH3-mimetics', that bind to pro-survival BCL-2 proteins to directly activate apoptosis of malignant cells. This Timeline article focuses on the discovery and study of BCL-2, the wider BCL-2 protein family and, specifically, its roles in cancer development and therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据